Scott Kopetz, MD, PhD

Trials

Studies that name Scott Kopetz, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:04 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT05292859 · Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

  Alaunos Therapeutics · completed · Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer · principal investigator
• Ph1/Ph2
  NCT05194735 · Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

  Alaunos Therapeutics · terminated · Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer · principal investigator
• N/A
  NCT05124743 · HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

  Alaunos Therapeutics · terminated · Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer · principal investigator
• Ph2
  NCT03549338 · Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

  Symphogen A/S · terminated · Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 13:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.